Commentary: Chemotherapy Dosing in Obese Patients With Cancer—The Need for Evidence-Based Clinical Practice Guidelines — JOP

* Copyright © 2011 by American Society of Clinical Oncology

Commentary: Chemotherapy Dosing in Obese Patients With Cancer—The Need for Evidence-Based Clinical Practice Guidelines

1. Gary H. Lyman, MD, MPH, FRCP(Edin)

* Gary H. Lyman, MD, MPH, FRCP(Edin), is Professor of Medicine and Director, Comparative Effectiveness and Outcomes Research, Duke University and the Duke Comprehensive Cancer Center. Contact him at gary.lyman@duke.edu .

Chemotherapy dosing in adult cancer patients has been based, largely by convention, on a patient's estimated body-surface area, despite very few supporting data. At the same time, substantial preclinical and clinical evidence suggests that reductions in standard dose–intensity chemotherapy may compromise disease-free and overall survival in the curative setting. 1– 4 In practice, however, the delivery of full standard dose–intensity chemotherapy is often not achieved for fear of excessive …
Commentary: Chemotherapy Dosing in Obese Patients With Cancer—The Need for Evidence-Based Clinical Practice Guidelines — JOP